A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability and Pharmacokinetics of LML134 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2016
At a glance
- Drugs LML 134 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Novartis
- 24 Apr 2016 Status changed from recruiting to completed.
- 15 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 15 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.